No difference in ischaemic risk or bleeding with low vs high-dose aspirin for secondary prevention: Lessons and questions from the ADAPTABLE trial Presented ByProf. William Schuyler Jones , Duke Clinical Research Institute, USA TrialADAPTABLE ConferenceACC 2021 9 July, 2021 23:03